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Abstract 
Allogeneic  hematopoietic  cell  transplantation  (HCT)  is  the  only  curative 
patients with myelodysplastic syndromes (MDS).  Most patients with MDS are older than 60 
years  and  age-associated  morbidities  limit  the  patients’  options  for  curative  transplant 
therapy.    Since  the  development  of  conditioning  regimens  with  re
limitations for HCT have waned for those patients with good performance status. This review 
will discuss the role of HCT for MDS based on prognostic features, the optimal timing of 
HCT, and outcomes based on patient age.
Introduction: Myelodysplastic syndrome (MDS) is 
a disease of ineffective hematopoiesis with the only 
potential  for  cure  by  hematopoietic  cell 
transplantation  (HCT)  from  a  healthy 
donor.    The  majority  of  patients  develop  MDS 
beyond 65 years of age when the incidence of the 
disease is greater than 15 per 100,000, as opposed 
to less than 4 per 100,000 in patients younger than 
65  years.
1    The  best  supportive  care  for  MDS 
includes hematopoietic growth factors, transfusions 
and  iron  chelating therapy.   Recently,  two  DNA
methyltransferase  inhibitors  (DMTi),  5
and  decitabine  (aza-2’-deoxycytidine),  and  the 
immune  modulator  lenalidomide  have  been 
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patients with myelodysplastic syndromes (MDS).  Most patients with MDS are older than 60 
associated  morbidities  limit  the  patients’  options  for  curative  transplant 
therapy.    Since  the  development  of  conditioning  regimens  with  reduced  toxicity,  the  age 
limitations for HCT have waned for those patients with good performance status. This review 
will discuss the role of HCT for MDS based on prognostic features, the optimal timing of 
HCT, and outcomes based on patient age.
Myelodysplastic syndrome (MDS) is 
a disease of ineffective hematopoiesis with the only 
potential  for  cure  by  hematopoietic  cell 
transplantation  (HCT)  from  a  healthy  stem  cell 
donor.    The  majority  of  patients  develop  MDS 
beyond 65 years of age when the incidence of the 
disease is greater than 15 per 100,000, as opposed 
to less than 4 per 100,000 in patients younger than 
The  best  supportive  care  for  MDS 
udes hematopoietic growth factors, transfusions 
and iron  chelating  therapy.    Recently, two  DNA-
methyltransferase  inhibitors  (DMTi),  5-azacitidine 
deoxycytidine),  and  the 
immune  modulator  lenalidomide  have  been 
approved by the US Food and Drug Administration 
for the treatment of MDS. 
2-4     Nevertheless, HCT 
remains  the  only  curative  treatment  for  MDS.  
Before  the  development  of  reduced  intensity 
regimens  a  decade  ago,  HCT  had  rarely  been 
offered to older patients, but its use has since
extended to patients age over 60 years. 
Classification  and  Prognostic  Groups
classification  and  prognostic  systems  have  been 
developed  in  an  endeavor  to  predict  disease 
outcomes  including  leukemia  transformation  and 
survival.  The  French
classification system initially recognized MDS as a 
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES
for  Myelodysplastic 
Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute. 
Moffitt Cancer  Center and  Research 
-745-3966.  E-mail: 
This  is  an  Open  Access  article  distributed  under  the  terms  of  the  Creative  Commons  Attribution  License
which permits unrestricted use, distribution, and reproduction in any medium, provided
Allogeneic  hematopoietic  cell  transplantation  (HCT)  is  the  only  curative  treatment  for 
patients with myelodysplastic syndromes (MDS).  Most patients with MDS are older than 60 
associated  morbidities  limit  the  patients’  options  for  curative  transplant 
duced  toxicity,  the  age 
limitations for HCT have waned for those patients with good performance status. This review 
will discuss the role of HCT for MDS based on prognostic features, the optimal timing of 
and Drug Administration 
Nevertheless, HCT 
remains  the  only  curative  treatment  for  MDS.  
Before  the  development  of  reduced  intensity 
regimens  a  decade  ago,  HCT  had  rarely  been 
offered to older patients, but its use has since been 
extended to patients age over 60 years. 
Classification  and  Prognostic  Groups:  Multiple 
classification  and  prognostic  systems  have  been 
developed  in  an  endeavor  to  predict  disease 
outcomes  including  leukemia  transformation  and 
survival.  The  French-American-British 
classification system initially recognized MDS as a Medit J Hemat Infect Dis 2010; 2(2): Open Journal System
clinical entity but has largely been replaced by the 
world  health  organization  (WHO)  classification.
5  
The International Prognostic Scoring System (IPSS) 
was developed to predict MDS prognosis, including 
time from diagnosis to acute myelogenous leukemia 
(AML)  progression  or death.    IPSS  incorporates 
blast  percentage,  number  of  cytopenias  and 
cytogenetic  risk  into  a  low,  intermediate-1, 
intermediate-2,  and  high  risk  categories.    For 
patients  with  high  risk  and  intermediate-2  (Int-2) 
disease, the average time from diagnosis to AML is 
0.2 and 1.1 years, respectively, and the average time 
to  death  is  0.4  and  1.2  years.
6    A  more  refined 
scheme  incorporates  transfusion  requirements, 
WHO category and cytogenetic risk into the WHO 
classification-based  Prognostic  Scoring  System 
(WPSS) which  is  a  time-dependent  stratification 
that allows predictions both at diagnosis, and after 
disease  advances.
7,8    More  recently  identified 
prognostic factors include transfusion dependence, 
pancytopenia,  marrow  fibrosis,  blast  clusters  and 
male gender, and these have been incorporated into 
improved prognostic models.
9–12
Induction  Chemotherapy  or  Autologous 
Transplantation:  These  classifications  and 
prognostic scoring systems can aid in determining 
the most realistic treatment goal and care. Whereas 
patients  with  low  risk  features  could  use  less 
intensive therapies with growth factors and immune 
modulation, more intensive treatment is required for 
controlling  advanced  disease.
13    High  dose 
chemotherapy  alone  is  effective  in  obtaining  a 
complete  remission in  some  patients,  however, 
remissions  are  short  and  relapses  occur  early 
resulting in a 5-year overall survival (OS) at 8%, 
according  to  a  meta-analysis  of  clinical  trials 
conducted at the M.D. Anderson in Houston, Texas, 
USA.
14  
Autologous  HCT  outcomes  have  not  faired 
better.    The  CRIANT  trial  evaluated  high  dose 
induction followed by consolidation chemotherapy 
followed  by  continued  chemotherapy  versus  an 
autologous  HCT  for  patients  without  an-HLA-
identical  sibling donor versus allogeneic HCT for 
those patients with such a donor.  More than half of 
the 341 patients enrolled did not achieve remission 
with  chemotherapy  and  did  not  proceed  on  trial.  
Among the eligible patients, 50 had a donor and 85 
did not do so: the 4-year OS was 45% versus 27%, 
respectively,  significantly  better  for  those  with  a 
donor (P= 0.020).  Among those without a donor, 
34  received  an  autograft  and  38  continued  with 
chemotherapy:  their  4-year  disease  free  survival 
(DFS)  was  30%  vs.  17%,  respectively,  not  a 
significant difference (P=0.98).
15  
Al-Ali et al analyzed the European Blood and 
Marrow Transplantation Group (EBMTG) data, and 
compared  593  patients  with  MDS  or  secondary 
AML  who  received  autologous  HCT  in  first 
complete remission (CR1) versus matched unrelated 
donor  (MUD)  HCT  with  untreated  disease  or  in 
CR1. The authors found 3-year relapse rates (RR) 
of  62  %  for  autologous  HCT,  30%  for  untreated 
MUD and 24% for MUD in CR1, and observed that 
relapse  after  autologous  HCT  continued  overtime 
while  relapse  after  MUD  HCT  reached  a  plateau 
before 3 years. In this analysis, age 20 – 40 years 
versus  >40  years  was  not  a  significant  factor  in 
outcomes in the allogeneic arm.
16
Allogeneic HCT: Multiple studies were designed to 
investigate  pre-HCT  factors  to  identify  which 
patient would gain the most benefit from allogeneic 
HCT.   
Deeg et al reported that FAB (French American 
British)  disease  stage,  cytogenetic  risk,  and  IPSS 
score  predict  the  incidence  of  relapse  after  HCT 
from compatible sibling or unrelated donors treated 
with  a  regimen  of  targeted  busulfan  and 
cyclophosphamide.  Patients with low risk IPSS had 
80% relapse-free survival (RFS) at 3 years versus 
29% for high risk patients.  The 3-year cumulative 
incidence of relapse was 0%, 6%, 29% and 42% for 
MDS with low risk disease, Int-1, Int-2 and High 
risk, respectively.
17 Donor matching also influenced 
survival after HCT.  Sibling and matched unrelated 
transplant recipients had a similar 3-year RFS (56% 
vs.  59%)  but  HLA  mismatched  transplants  were 
associated with decreased RFS (27%). FAB stage, 
refractory  anemia  (RA),  RA  with  excess  blasts 
(RAEB)  or  RAEB in  transformation,  affected  the 
relapse  risk  with  a  3-year  RFS  of  68%,  45%  or 
33%,  respectively,  after  sibling  transplants  and 
70%,  40%  or  17%,  respectively,  after  matched 
unrelated donor transplants. 
17
Sierra et al reported international bone marrow 
transplant registry (IBMTR) data showing a 40% 3-
year  average  RFS  with  sibling  donor  transplants, 
and  found  that  IPSS  category  and  percentage  of 
marrow  blasts  at time  of  HCT influenced  relapse 
risk.
18   The impact of FAB stage was also found by 
the  Castro-Malaspina  et  al,  in  a  retrospective 
analysis of unrelated donor transplants facilitated by
the national donor marrow program (NMDP).  The 
two  year  DFS,  relapse  incidence  and  transplant 
related mortality (TRM) were 29%, 14% and 54%, 
respectively,  advanced  FAB  stage  was  associated Medit J Hemat Infect Dis 2010; 2(2): Open Journal System
with an increased risk of relapse, and lower FAB 
stage with increased DFS.
19  
Guardiola et al analyzed associations of donor 
source with outcome in a multi-center retrospective 
analysis of 234 sibling HCT in patients with MDS.  
The authors compared bone marrow (BM) (n=132) 
with  102  with  peripheral  blood  (PB)  donor 
transplants, and found a 2-year DFS of 50% with 
PB versus 39% with BM [RR, 0.79; 95% CI, 0.54-
1.14, P < .20],  a TRM of 36% with PB versus 42% 
with BM [OR 0.33, 95% CI 0.15-0.73, P<0.001], 
and a relapse incidence of 13% with PB versus 38% 
with BM [RR 0.29, 95% CI, 0.13-0.62, P = .20]
20  
Consistent  with  results  of  BM  versus  PBSC 
prospective  trials  in  patients  with  high  risk 
malignancy, the Guardiola paper has set the use of 
PBSC  as  the  preferred  stem  cell  source  for 
allogeneic HCT in the treatment of MDS.
40
de  Witte  et  al  reported  that  a  longer  interval 
from  diagnosis  to  transplant  for  RA  patients  is 
associated with worse survival.  They analyzed 374 
transplants with RA in the EBMT registry, 191 had 
data to calculate the IPSS score. Fifty-nine percent 
were age greater than 50 years, and the majority had 
PB grafts (84%).    The four-year  OS, RFS, NRM 
and  RR  were  52%,  48%,  37%  and  15%, 
respectively.    By  multivariate  analysis,  transplant 
within  12  months  of  diagnosis  was  a  favorable 
factor for survival (HR 1.4, P=0.05).
22
Cutler  et  al  addressed  the  optimal  timing  of 
MDS patients proceeding to HCT using a decision 
analysis from Center for the International Blood and 
Marrow Transplant Research (CIBMTR) registries 
and  the  Fred  Hutchinson  Cancer  Center.    Adult 
patients  age  18  - 60  years  were  included.    The 
model found  that  early  transplantation  resulted  in 
improved survival for patients with INT-2 and high-
risk  MDS,  but  not  for  those  with  earlier  stage 
disease.  Patients  with  low  risk  disease  had  an 
estimated  life  expectancy  of  6.51  year  when 
transplanted at diagnosis vs. 7.21 years if transplant 
occurs  at  disease  progression.  As  the  low  risk 
cohort did not demonstrate an advantage for early 
HCT,  they  should  wait  for  HCT  until  disease 
progression.
21 Therefore,  while  delaying  HCT 
optimizes  survival  of  early  MDS  patients  with 
indolent  disease  and  a  relatively  long  life 
expectancy,  it  paradoxically  makes  HCT  a  less 
effective  therapy  for  those  patients  with  more 
aggressive disease.
Pre-Transplant  Chemotherapy:  There  is  an 
uncertain role of pre-transplant therapies for MDS 
while patients are waiting for a suitable donor. The 
studies  noted  above  found  MDS  risk  factors  that 
predicted  outcomes  of  allogeneic  HCT.  Several 
institutions  have  explored  the  efficacy  of 
chemotherapy before HCT to reduce the MDS risk, 
with the hope to decrease the rates of relapse and 
improve HCT outcomes.  Nakai et al described the 
outcomes of 238 MDS patients undergoing a sibling 
donor HCT: OS at 5 years was similar for patients 
who received pre-HCT chemotherapy and obtained 
a  remission  and  those  who  did  not  receive  prior 
chemotherapy 57% vs. 54% P=0.81.
23  
Oran et al reported on MDS (n = 30) and AML 
(n  =  82)  patients  who  were  given  fludarabine-
melphalan  as  conditioning.    Twenty-three  of  the 
MDS  patients  received  pre-HCT  chemotherapy.  
Results  varied  with  remission  status,  with  2-year 
OS of 66% for patients in CR and 23% for those 
with  active  disease  and  circulating  blasts.  
Cumulative incidence of nonrelapse mortality at 2 
years was 20% for patients who had CR and 56% 
for those who did  not have CR.  The fraction  of 
patients  who  received  chemotherapy  and  did  not 
proceed to HCT was not reported.
24  
Scott et al examined 150 patients with MDS or 
AML arising out of MDS. Among the 38 patients 
who  received  a  non-myeloablative  transplant 
(NMT),  24  had  been  treated  with  pre-transplant 
induction chemotherapy, with 20 achieving CR.  At 
3  years,  OS,  DFS,  disease  progression,  and 
nonrelapse  mortality  were  27%,  28%,  41%,  and 
31%,  respectively.  There  were  no  survival 
differences between the 112 patients who received 
standard  myeloablative  conditioning  and  the  38 
who received a nonmyeloablative conditioning.
25
The  question  of  whether  pretransplant 
‘leukemia-type’  induction  chemotherapy  provides 
an  advantage  to  MDS  patients  treated  with 
allogeneic HCT is under investigation through the 
Allo-MDS, 2x2, phase III, prospective, randomized 
trial by the EBMTG.
Pre-Transplant  DNA  Methyltransferase 
Inhibitors:  The  approval  of  5-azacitidine  and 
decitabine for the treatment of MDS has provided 
an  alternative  strategy  to  prevent  disease 
progression  in  transplant-eligible  patients.    In  a 
prospective  randomized  trial,  5-azacitidine 
prolonged survival compared to standard supportive 
care in 191 patients with MDS.
2,3  Sixty percent of 
the patients had a response (complete response in 
7%,  partial response  in  16% and  improvement in 
37%)  as  compared  to  5%  response  using  the 
standard  supportive  care.  Median  survival  was 
increased (18 months versus 11 months) and there 
was  a  decrease  in  the  time  to  transformation  to 
leukemia (21 months versus 13 months). The drug Medit J Hemat Infect Dis 2010; 2(2): Open Journal System
was well tolerated with the most common treatment 
related  toxicity  of  myelosuppression  and 
concomitant  infections.    Due  to  the  survival 
advantages reported with 5-azaciticine and the fact 
that it is relatively well tolerated, its use has become 
widespread.    Patients  are  typically  treated  until 
there is no longer a benefit. 
Decitabine  has  also  demonstrated  efficacy  in 
treating MDS.  Kantarjian et al found that 30% or 
patients  responded  but  there  was  no  significant 
improvement in survival.   Patients with de novo 
MDS had a median OS of 12.6 versus 9.4 months in 
those treated versus standard of care (p=ns). Time 
to  progression  to  AML  was  decreased  from  a 
median of 12.1 versus 7.8 months (P = 0.16).
4   The 
reason  for  the  decitabine  studies  failure  to  show 
improved  survival  over  standard  of  care  controls 
remains unclear.
During  the months  needed  to  obtain a donor, 
patients  are  at  risk  of  disease  progression, 
transformation to AML, complications of treatment, 
and to become ineligible for HCT for any of these 
reasons. As the median time to death for IPSS high 
risk and intermediate risk MDS is 0.4 and 1.2 years. 
Therefore, a large fraction of patients with high risk 
MDS could deteriorate or die while waiting for a 
suitable donor or for the transplant to be scheduled.  
DMTi pretransplant could provide a bridge to HCT 
by  controlling  MDS  and  delaying  disease 
progression  during  the  donor  search.    It  is  also 
possible  that  pre-HCT  DMTi  render  patients 
ineligible for HCT because of complications.  There 
are currently no data on the proportion of patients 
that  are  treated  with  DMTi  that  are  eligible  to 
proceed  to  HCT.  However,  post-transplant 
outcomes  on  patients  receiving  5-azacitadine  or 
decitabine are available.   Field et al compared 54 
patients with MDS or CMML receiving pre-HCT 5-
azacitidine (n=30)  or  no 5-azacitidine  (n=24) and 
outcomes were similar.
26   Cogle et al examined 8 
patients  receiving  pre-HCT  5-azacitidine  and 
reported full donor chimerism in both granulocyte 
and  lymphocyte  subsets. 
27    Two  groups  have 
described  pre-HCT  decitabine  effect  on  HCT.  
Lubbert  et al  described 15  patients  with  MDS or 
AML and De Padua et al reported on 17 patients 
with  MDS who received  pre-transplant  decitabine 
prior to HCT.
28,29  Both groups found no increased 
toxicity or adverse effects on HCT outcomes. 
The answer to the role of DMTi pre-transplant 
therapy  remains  under  investigation.  Because 
induction  chemotherapy  can  increase  the  risk  of 
death  or  prevent  patients  proceeding  to  HCT 
because of toxicities, DMTi’s are an alternative for 
patients  to  control  the  disease  while  they  await 
HCT.  
Age and Reduced Intensity Conditioning (RIC): 
Most patients are diagnosed with MDS when they 
are  older  than  60  years.    Until  the  ‘90s,  older 
patients  have  been  excluded  from  HCT  due  to 
intolerable  risk  of  non-relapse  mortality.    Older 
patients also have higher  risk MDS than  younger 
patients.  Recent  understanding  that  donor 
engraftment  does  not  require  myeloablative 
conditioning  and  that  disease  control  is  in  part 
provided by alloreactive donor  immune cells, has 
allowed designing reduced intensity regimens that 
are  more  tolerable,  have  decreased  mortality  and 
have increased  the  age  that  HCT  can  be  offered. 
17,30,31,38 Several  studies  focusing  on  patients  with 
MDS  and  AML,  have  reported  comparisons  of 
reduced  intensity  versus  conventional  preparative 
regimens and demonstrated comparable disease-free 
survival  (DFS)  (39%  to  50%). 
32,33,34 Reduced 
intensity  regimens  tested  in  those  reports  include 
fludarabine, low dose TBI, busulfan or melphalan. 
Although  the  use  of  reduced  intensity 
conditioning  regimens  has  decreased  transplant-
related mortality  and  extended  HCT  to  older  and 
frailer  patients,  the  risk  of  relapse  has  increased.  
Several reports have assessed the increased risk of 
relapse  with  the  use  of  reduced  intensity 
conditioning  regimens  in  MDS.  Nakamura  et  al 
analyzed  results  of  a  fludarabine-melphalan 
regimen in 43 MDS patients, including 15 who had 
progressed  to  AML.  The  two-year  OS,  DFS, 
relapse, and transplant-related mortality were 54%, 
51%, 16%, and 35%, respectively.  Donor source 
was not a factor in survival, although there was less 
relapse  when  unrelated  donors  were  used  (P  = 
.02).
35 Chan  et  al  described  a  novel  regimen  of 
pentostatin,  total  body  irradiation,  and 
photopheresis  in  18  patients  with  MDS.    In  this 
study,  2  patients  did  not  engraft  and  2  did  not 
achieve initial CR and died of disease progression. 
One-year OS, DFS, and nonrelapse mortality were 
65%, 64%, and 14%, respectively. 
36 Kroger et al 
reported on 12 high-risk MDS patients who were 
given  fludarabine,  busulfan,  and  ATG  induction.  
Two-year  OS  and  DFS  were  26% and  12%, 
respectively, with 4 patients dying in remission.
37
McCune et al reported on the effect of age on HCT 
in  patients  with  AML  (536)  and  MDS  (535) 
utilizing  data  from  the  Center  for  international 
Blood and marrow Transplant Research (CIBMTR). 
Among patients with MDS, age was not associated 
with survival, relapse or nonrelapse mortality at 2 
years.  OS was 35% in the cohort aged 55-59, 45% Medit J Hemat Infect Dis 2010; 2(2): Open Journal System
Figure 1.  Treatment algorithm for low/int-1 risk MDS (modified from NCCN).
aged 60-64, and 38% greater than 65. 
38   Field et al 
reported  on  121  patients  with  MDS  or  CMML 
receiving fludarabine plus a myeloablative dose of 
targeted busulfan.  Eight-nine were older than 50 
years and fifteen older than 65 years.  There were 
no significant  differences  in OS (P=0.7) or  NRM
(P=0.15), but there was an increase risk of relapse 
with increasing age (P=0.002).  Two-year OS  was 
49% (<50 years), 47% (50-59 years), 54% (60-64 
years) and 38% (>65 years). Use of pre-HCT DMTi 
or  unrelated  donors  did  not  affect  outcomes.
31  
Utilization  of  RIC  methods  permit  proceeding  to 
HCT in selected patients up to 75 years of age with 
no or minimal co-morbidities.
Finding  A  Suitable  Donor:  Finding  a  suitable 
donor before disease progression is a challenge in 
MDS due to rapid progression in intermediate and 
high risk disease.  On the average, the time from the 
initial  consult  for  transplant  to  the  donor  cell 
infusion  (including  the  time  to  identify  a  donor, 
obtain  insurance  approval  and  complete  the  pre-
transplant evaluation) ranges from 3 to 4 months.  If 
the siblings are not a match, then an unrelated donor 
search should be initiated.  Donor relation, whether 
sibling  or  unrelated,  has  not  been  a  significant 
factor for survival of patients regardless of age.  
Anasetti et al investigated the time it takes to 
identify an unrelated donor match.  The probability 
of finding an unrelated donor HLA-A, B, C, DRB1 
allele match [7 or 8 of 8] is 89% (Caucasians), 77% 
(Hispanic)  and  64%  (African-American).  No 
suitable matches were found  in 11% (Caucasian), 
23%  (Hispanic)  and  37%  (African  American).  
Time to identifying the 1st donor was a median 20 
days [11-59, 95% CI].  The time from identification 
of donor to cell infusion was a median of 81 days 
[45-199, 95% CI]. 
39 Field et al reported that among 
255 MDS patients with MDS or CMML evaluated 
for  HCT,  88%  found  a  suitable  donor,  and  70% 
with a donor proceeded to HCT.
31Medit J Hemat Infect Dis 2010; 2(2): Open Journal System
Figure 2.  Treatment algorithm for int-2/high risk MDS (modified from NCCN).
Treatment  Algorithm:  Figure  1 and  Figure  2
illustrate treatment decision points in Low risk/Int-1 
and Int-2/High risk MDS, according to the National 
Cancer  Center  Network  MDS  consensus  panel.   
For  those  patients  with  low  risk  disease  where 
anemia is the sole unfavorable risk feature and who 
have  low  transfusion  requirements,  watchful 
waiting is recommended, particularly in those age 
less than 50 years. Treatment options for those with 
myeloblasts  <  5%  but  with  concomitant  adverse 
features such as increased transfusion needs, severe 
cytopenias, multi-lineage dysplasia, age greater than 
50  years  or  therapy  related  MDS  include 
immunosuppressive  therapy,  hypomethylating 
agents  or  enrolling  in  an  investigational  trial. 
Patients  with  Del  (5)  (q31.1)  should  receive 
lenalidomide.    All  except  those  with  low  risk 
disease should be HLA-typed and a donor search 
initiated at diagnosis. At time of progression, HCT 
can  be  offered  to  those  with  an  adequate 
performance status, if an available donor exists.
Patients with IPSS Int-2 or high risk, who are 
potential transplant candidates because of adequate 
organ  function  and  minimal  comorbidities  should 
have  a  donor  search  initiated  at  diagnosis  and 
proceed to HCT.  DMTi agents can be utilized as a 
bridge to stabilize the disease until  time of HCT.  
Those without a suitable  donor should be offered 
therapies via an investigational clinical trial.
Conclusions: HCT  remains  the  only  curative 
therapy for high risk MDS.  Decreased toxicity of 
the  pre-transplant  conditioning  regimen  provides 
the  opportunity  to  treat  suitable  patients  with 
allogeneic HCT up to 75 years of age.  Treatment 
with  DMTi  may  allow  more  patients  to  reach 
transplant,  however,  prevention  of  post  transplant 
relapse remains a challenge.  
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